Our earlier study had shown that low concentrations of monocrotophos (MCP) elicited dopaminergic features of Parkinson’s disease (PD) in the nematode Caenorhabditis elegans. In the present study, the effect of low doses of MCP on the striatal dopaminergic neurons was investigated using the mouse model system. MCP was initially screened for its ability to cause any neurobehavioral deficits and alterations in the dopaminergic system in Swiss albino mice, aged 8 weeks and weighing 25–30 g, with repeated doses at 0.3 and 0.6 mg/kg body weight (b.w.)/day for 7 days and 30 days. Mice were treated with four intraperitoneal injections for every 2 h with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) at the dosage of 14 mg/kg b.w. MCP was administered to these mice at the above-mentioned doses for 7 days. Mice administered with MCP alone revealed a significant (p < 0.05) reduction in the dopamine (DA) content at both 7 and 30 days and showed a significant (p < 0.05) increase in neurobehavioral deficits. Interestingly, when MCP was administered for 7 days to MPTP-treated mice, further significant decrease in both DA content and increase in neurobehavioral deficits were apparent. The extent of reactive oxygen species and lipid peroxidation were markedly increased, while the ratio of reduced to oxidized glutathione levels were significantly decreased (p < 0.05) in the treated mice as compared to the control. Significant histopathological alterations and a marked reduction in the number of tyrosine hydroxylase positive cells were evident in striatum of mice treated with higher doses of MCP. These changes were comparable to that seen in mice treated with MPTP and post-administered lower doses of MCP. Our findings suggest that MCP per se has the propensity to induce pathological changes in the dopaminergic neurons as well as augment the degeneration in a compromised nigrostriatal system such as that in PD.
AliSFChandraOHasanM (1980) Effects of an organophosphate dichlorvos on open field behavior and locomotor activity, correlation with regional brain monoamine levels. Psychopharmacology68: 37–42.
2.
AliSJRajiniPS (2012) Elicitation of dopaminergic features of Parkinson’s disease in C. elegans by monocrotophos, an organophosphorus insecticide. CNS and Neurological Disorders Drug Targets11(8): 993–1000.
3.
AltuntasIDelibasNSutcuR (2002) The effects of organophosphate insecticide methidathion on lipid peroxidation and anti-oxidant enzymes in rat erythrocytes: role of vitamins E and C. Human and Experimental Toxicology21(12): 681–685.
4.
BagchiDBagchiMHassounEA. (1995) In vitro and in vivo generation of reactive oxygen species, DNA damage and lactate dehydrogenase leakage by selected pesticides. Toxicology104(1–3): 129–140.
5.
Ben-ShaulYBenMoyal-SegalLBen-AriS. (2006) Adaptive acetylcholinesterase splicing patterns attenuate 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced Parkinsonism in mice. European Journal of Neuroscience23(11): 2915–2922.
6.
BinukumarBKBalAKandimallaRJ. (2010) Nigrostriatal neuronal death following chronic dichlorvos exposure: crosstalk between mitochondrial impairments, a synuclein aggregation, oxidative damage and behavioral changes. Molecular Brain3: 1–35.
7.
BlumDTorchSNissouMF. (2001) 6-hydroxydopamine-induced nuclear factor kappa B activation in PC12 cells. Biochemical Pharmacology62(4): 473–481.
8.
BraakHDel TrediciK (2009) Neuroanatomy and pathology of sporadic Parkinson’s disease. Advances in Anatomy, Embryology and Cell Biology201: 1–119.
9.
BraungartEGerlachMRiedererP. (2004) Caenorhabditis elegans MPP+ model of Parkinson’s disease for high-throughput drug screenings. Neurodegenerative Diseases1(4–5): 175–183.
10.
BuegeJAAustSD (1978) Microsomal lipid peroxidation. Methods in Enzymology52: 302–310.
11.
BushnellPJMoserVC (2006) Behavioral toxicity of cholinesterase inhibitors. In: GuptaRC (ed) Toxicology of Organophosphate and Carbamate Compounds. San Diego: Elsevier, pp. 347–360.
12.
CostaLG (2006) Current issues in organophosphate toxicology. Clinica Chimica Acta366 (1–2): 1−13.
13.
CraggSJ (2006) Meaningful silences: how dopamine listens to the ACh pause. Trends in Neuroscience29: 125–131.
14.
DateIFeltenDLFeltenSY (1990) Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis. Brain Research519: 266–276.
15.
De LauLMLBretelerMMB (2006) Epidemiology of Parkinson’s disease. Lancet Neurology5(6): 525–535.
16.
DuvoisinRC (1967) Cholinergic-anticholinergic antagonism in Parkinsonism. Archives of Neurology17(2): 124–136.
17.
DuysenEGLiBXieW. (2001) Evidence for nonacetylcholinesterase targets of organophosphorus nerve agent: supersensitivity of acetylcholinesterase knockout mouse to VX lethality. Journal of Pharmacology and Experimental Therapeutics299(2): 528–535.
18.
EllmanGLDiane CourtneyKAndresVJr. (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochemical Pharmacology7(2): 88–95.
19.
FornoLS (1996) Neuropathology of Parkinson’s disease. Journal of Neuropathology and Experimental Neurology55(3): 259–272.
20.
GalaniFBocqueneG (1991) Semi automated colorimetric and enzymatic assay for aquatic organisms using plate readers. Water Research25(20): 147–150.
21.
GötzJSchildAHoerndliF. (2004) Amyloid induced neurofibrillary tangle formation in Alzheimer’s disease: insight from transgenic mouse and tissue-culture models. International Journal of Developmental Neuroscience22(7): 453–446.
22.
GruntekNEKarpovaaEKAlekseevAA. (2005) Effect of dopamine on juvenile hormone metabolism and fitness in Drosophila virilis. Journal of Insect Physiology51(9): 959–968.
23.
GultekinFDelibasNYasarS. (2001) In vivo changes in antioxidant systems and protective role of melatonin and a combination of vitamin C and vitamin E on oxidative damage in erythrocytes induced by chlorpyrifos-ethyl in rats. Archives of Toxicology75(2): 88–96.
24.
HadjiconstantinouMHubbleJPWemlingerTA. (1994) Enhanced MPTP neurotoxicity after treatment with isoflurophate or cholinergic agonists. Journal of Pharmacology and Experimental Therapeutics270(2): 639–644.
25.
HatcherJMPennellKDMillerGW (2008) Parkinson’s disease and pesticides: a toxicological perspective. Trends in Pharmacological Sciences29(6): 322–329.
26.
HissinPJHilfR (1976) A fluorometric method for determination of oxidized and reduced glutathione in tissues. Analytical Biochemistry74: 214–226.
27.
HodaieMNeimatJSLozanoAM (2007) The dopaminergic nigrostriatal system and Parkinson’s disease: molecular events in development, disease, and cell death, and new therapeutic strategies. Neurosurgery60: 17–28.
28.
Infante-RivardCLabudaDKrajinovicM. (1999) Risk of childhood leukemia with exposure to pesticides and with gene polymorphisms. Epidemology10(5): 481–489.
29.
Jackson-LewisVPrzedborskiS (2007) Protocol for the MPTP mouse model of Parkinson’s disease. Nature Protocols2(1): 141–151.
30.
Jackson-LewisVJakowecMBurkeRE. (1995) Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration4(3): 257–269.
31.
KannanKJainSK (2000) Oxidative stress and apoptosis. Pathophysiology7(3): 153–163.
32.
KaranthSLiuJMirajkarN. (2006) Effects of acute chlorpyrifos exposure on in vivo acetylcholine accumulation in rat striatum. Toxicology and Applied Pharmacology216: 150–156.
33.
KarenDJLiWHarpPR. (2001) Striatal dopaminergic pathways as a target for the insecticides permethrin and chlorpyrifos. Neurotoxicology22(6): 811–817.
34.
KaziAIOommenA (2012) The effect of acute severe monocrotophos poisoning on inhibition, expression and activity of acetylcholinesterase in different rat brain regions. NeuroToxicology33: 1284–1290.
35.
KestonASBrandtR (1965) The fluorometric analysis of ultramicro quantities of hydrogen peroxide. Analytical Biochemistry11: 1–5.
36.
LalouxCDeramburePKreislerA. (2008) MPTP-treated mice: long-lasting loss of nigral TH-ir neurons but not paradoxical sleep alterations. Experimental Brain Research186: 635–642.
37.
Le CouteurDGMcLeanAJTaylorMC. (1999) Pesticides and Parkinson’s disease. Biomedicine and Pharmacotherapy53(3): 122–130.
38.
LewyFH (1912) Paralysis agitans pathologische anatomie. In: LewandowskiM (ed) Handbuch der Neurologie. Vol 3. Berlin: Springer-Verlag, pp. 920–933.
39.
Lopez-CrespoGACarvajalFFloresP. (2007) Time course of biochemical and behavioural effects of a single high dose of chlorpyrifos. Neurotoxicology28: 541–547.
40.
LothariusJBrundinP (2002) Pathogenesis of Parkinson’s disease: dopamine, vesicles and α-synuclein. Nature Reviews Neuroscience3(12): 932–942.
41.
LowryOHRosenbroughNJFarrAL. (1951) Protein measurement with folin phenol reagent. Journal of Biological Chemistry193(1): 265–275.
42.
MandhaneSNChopdeCT (1995) Neurobehavioral effects of acute monocrotophos administration in rats and mice. Indian Journal of Pharmacology27(4): 245–249.
43.
Masoud AKiranSandhirR (2009) Impaired mitochondrial functions in organophosphate induced delayed neuropathy in rats. Cellular and Molecular Neurobiology29(8): 1245–1255.
44.
MiglioreLCoppedèF (2009) Environmental-induced oxidative stress in neurodegenerative disorders and aging. Mutation Research674(1–2): 73–84.
45.
MorenoMCanadasFCardonaD. (2008) Long-term monoamine changes in the striatum and nucleus accumbens after acute chlorpyrifos exposure. Toxicology Letters176: 162–167.
46.
NasutiCGabbianelliRFalcioniML. (2007) Dopaminergic system modulation, behavioral changes and oxidative stress after neonatal administration of pyrethroids. Toxicology229(3): 194–205.
47.
PereraPMJayamannaSFHettiarachchiR. (2009) A phase II clinical trial to assess the safety of clonidine in acute organophosphorus pesticide poisoning. Trials10: 73.
48.
PittmanJTDoddCAKleinBG (2003) Immunohistochemical changes in the mouse striatum induced by the pyrethroid insecticide permethrin. International Journal of Toxicology22: 359–370.
49.
PriyadarshiAKhuderSASchaubEA. (2001) Environmental risk factors and Parkinson’s disease: a meta analysis. Environmental Research86(2): 122–127.
50.
RajputAHUittiRJSternW. (1987). Geography, drinking water chemistry, pesticides and herbicides and the etiology of Parkinson’s disease. Canadian Journal of Neurological Sciences14(3): 414–418.
51.
SalminenOMurphyKLMcIntoshJM. (2004) Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Molecular Pharmacology65: 1526–1535.
52.
SanbergPRBunseyMDGiordanoM. (1988) The catalepsy test: its ups and downs. Behavioral Neurosciences102(5): 748–759.
53.
SarinSGillKD (1998) Dichlorvos induced alterations in glucose homeostasis: possible implications on the state of neuronal function in rats. Molecular and Cellular Biochemistry199(1–2): 87–92.
54.
SemchukKMLoveEJLeeRG (1991) Parkinson’s disease and exposure to rural environmental factors: a population based case-control study. Canadian Journal of Neurological Sciences18(3): 279–286.
55.
ShahMDIqbalM (2010) Diazinon-induced oxidative stress and renal dysfunction in rats. Food Chemistry and Toxicology48(12): 3345–3353.
TannerCMOttmanRGoldmanSM. (1999) Parkinson’s disease in twins: an etiologic study. Journal of the American Medical Association281(4): 341–346.
58.
TerryAVJrStoneJDBuccafuscoJJ. (2003) Repeated exposures to subthreshold doses of chlorpyrifos in rats: hippocampal damage, impaired axonal transport, and deficits in spatial learning. Journal of Pharmacology and Experimental Therapeutics305(1): 375–384.
59.
ThomasBBealMF (2007) Parkinson’s disease. Human Molecular Genetics16(2): 183–194.
60.
ViswanathVWuYBoonplueangR. (2001) Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced Parkinson’s disease. The Journal of Neuroscience21(24): 9519–9528.
61.
WootenGF (1997) Neurochemistry and neuropharmacology of Parkinson’s disease. In: WattsRL (ed) Movement Disorders: Neurological Principles and Practice. New York: McGraw-Hill, pp. 153–160.
